(Q21260262)

Dimensions Publication ID

Dimensions

1010271771

19 August 2022

Hugo A Jørgensen

series ordinal

2

author given names

Hugo A

author last names

Jørgensen

1 reference

Dimensions Publication ID

Dimensions

1010271771

Creative Commons Attribution 2.0 Generic

19 August 2022

language of work or name

English

0 references

publication date

2008

0 references

25 April 2008

1 reference

25 January 2021

1 reference

25 January 2021

8

0 references

issue

1

0 references

page(s)

31

0 references

copyright license

1 reference

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

Europe PubMed Central

25 January 2021

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Funding source, trial outcome and reporting quality: are they related? Results of a pilot study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Zotepine for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Aripiprazole for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Olanzapine for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Quetiapine for schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

New generation antipsychotics for first episode schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

12 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

12 September 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Defining and measuring clinical effectiveness in the treatment of schizophrenia

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

A meta-analysis of the efficacy of second-generation antipsychotics

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

The Mount Sinai conference on the pharmacotherapy of schizophrenia

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Risperidone versus other atypical antipsychotic medication for schizophrenia

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Ziprasidone for schizophrenia and severe mental illness

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Newer atypical antipsychotic medication versus clozapine for schizophrenia

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

The association between funding by commercial interests and study outcome in randomized controlled drug trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Practice regarding antipsychotic therapy: a cross-sectional survey in two Norwegian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Patterns of risperidone prescription: a utilization study in south-west France

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

Selection Bias in Clinical Trials With Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-8-31

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Olanzapine versus risperidone in newly admitted acutely ill psychotic patients

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2386457

The uncertainty principle and industry-sponsored research

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18439263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18439263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18439263

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-244X-8-31

1 reference

Dimensions Publication ID

1010271771

0 references

Fatcat ID

release_czelowdimra2rkeb675ram762e

0 references

1 reference

1 reference

PubMed publication ID

18439263

1 reference